联合探针法快速检测EGFR突变

目的:表皮生长因子受体(epidermal growth factor receptor,EGFR)突变尤其是19外显子E746_A750del和21外显子 L858R突变与接受TKIs治疗的非小细胞肺癌患者的临床预后相关,这就意味着检测EGFR突变在临床治疗中起着重要作用?因此,建立一种快速简单而经济的检测EGFR突变的方法能够有效缓解患者经济负担?方法:通过不对称PCR和联合探针(APCR-JP)快速检测EGFR突变?本研究中收集37例非小细胞肺癌患者肿瘤组织进行APCR-JP检测?结果:发现17例(45.9%)19外显子突变和8例(21%)21外显子突变,此结果与测序结果一致?结论:APCR-JP能够检测EGFR突变,为临床治疗提供依据?

Rapid and sensitive detection of EGFR drug response mutation by Junction probe technology

Objective:Epidermal growth factor receptor(EGFR)mutation,particularly E746_A750del and L858R,is thought to be associated with clinical outcomes of patients with non-small cell lung cancer(NSCLC) receiving TKIs treatment,suggesting that EGFR mutation test may play an important role in clinical decision. So,establishment of a rapid,simple and cost-effectiveness EGFR mutation test method can effectively relieve the financial burden of patients. Methods:We established a rapid and sensitive assay for detecting EGFR mutation by asymmetrical PCR and Junction Probe (APCR-JP). In this study,37 NSCLC tissue samples were detected by APCR-JP assay. Results:Seventeen samples (45.9%) carried 19del mutation and 8 samples (21%) had L858R mutation,which are consistent with the results of direct sequencing. Conclusion:These results suggest that APCR-JP could be used in EGFR mutation detection and provide imformation for clinical decision.